Expert Interview
Discussing Veradermics' VDPHL01, an Extended-Release Oral Minoxidil (Non-Hormonal Therapeutic) for Androgenetic Alopecia
Ticker(s): MANE, LLY, PFEInstitution: Yale
- Associate Professor of Dermatology Yale School of Medicine
- Currently manages 300 patients with androgenetic alopecia and 120 patients with atopic dermatitis and 60 with vitiligo.
- Pioneered the use of JAK Inhibitors in cutaneous diseases and has published extensively on their use in atopic dermatitis, vitiligo and alopecia areata, among other dermatologic diseases.
How many patients do you manage with Androgenetic Alopecia?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for VDPHL01, an Extended-Release Oral Minoxidil (Non-Hormonal Therapeutic) as a potential treatment for Androgenetic Alopecia?
Added By: lilly_adminPhase 3 is expected to read out in males - Thoughts on real-world safety of the extended-release (ER) formulation and the reliability of patient-reported outcome (PRO) endpoints compared to objective hair counts?
Added By: lilly_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
